TABLE 4.

Subgroup analysis results of overall response and cytokine-release syndrome rate.

Subgroups	Overall response rate			Cytokine-release syndrome rate
	No. Of trials	ORR (95% CI)	P for difference	No. Of trials	CRS (95% CI)	P for difference
Mean age (years)			0.016			0.074
≥55	15	0.84 (0.78; 0.92)		15	0.83 (0.77; 0.91)
<55	4	0.96 (0.90; 1.03)		4	0.92 (0.86; 0.98)
Dose			0.045			—
high dose group ≥200 × 10^6cells or 5 × 10^6 cells/kg	12	0.82 (0.75; 0.90)		—	—
low dose group <200 × 10^6cells or 5 × 10^6 cells/kg	18	0.92 (0.87; 0.98)		—	—
Antigen-recognition domain origin			0.010			0.018
Human	11	0.91 (0.83; 0.99)		11	0.83 (0.73; 0.94)
Murine	6	0.76 (0.69; 0.85)		6	0.77 (0.66; 0.90)
Llama	2	0.92 (0.86; 0.99)		2	0.94 (0.90; 0.98)
Costimulatory molecule			0.351			0.677
4-1BB	17	0.88 (0.82; 0.94)		17	0.86 (0.80; 0.92)
others	4	0.84 (0.76; 0.92)		4	0.82 (0.65; 1.02)
Loading			0.066			0.347
Lentiviral	7	0.92 (0.84; 1.00)		7	0.93 [0.87; 0.99]
Retrovirus	2	0.78 ((0.68; 0.91)		2	0.58 (0.22; 1.54)
Median time from diagnosis (years)			0.263			0.220
≥4	6	0.84 (0.75; 0.94)		6	0.88 (0.82; 0.94)
<4	5	0.91 (0.83; 1.00)		5	0.75 (0.58; 0.96)
Lines of prior treatment			0.011			0.369
≥8	3	0.98 (0.90; 1.07)		3	0.91 (0.77; 1.06)
<8	17	0.85 (0.79; 0.91)		17	0.84 (0.78; 0.90)
Prior ASCT (%)			0.068			0.775
≥75	7	0.78 (0.68; 0.90)		7	0.85 (0.77; 0.93)
<75	11	0.90 (0.85; 0.97)		11	0.83 (0.73; 0.93)
High-risk cytogenetics (%)			0.783			0.116
≥48	10	0.88 (0.80; 0.98)		10	0.90 (0.86; 0.95)
<48	9	0.86 (0.79; 0.94)		9	0.82 (0.73; 0.91)
Extramedullary disease (%)			0.489			0.360
≥29	6	0.88 (0.80; 0.97)		6	0.88 (0.82; 0.96)
<29	6	0.83 (0.72; 0.95)		6	0.81 (0.69; 0.96)
ECOG≥3 level (%)			0.001			0.06
≥25	3	0.78 (0.70; 0.86)		3	0.58 (0.36; 0.96)
<25	3	0.94 (0.89; 0.98)		3	0.94 (0.90; 0.98)
ISS≥3 level (%)			0.046			0.481
≥28	5	0.84 (0.77; 0.91)		5	0.90 (0.83; 0.97)
<28	4	0.94 (0.87; 1.01)		4	0.83 (0.70; 1.00)
mAb exposed (%)			0.263			0.143
≥39	6	0.79 (0.68; 0.93)		6	0.86 (0.78; 0.96)
<39	5	0.88 (0.80; 0.97)		5	0.70 (0.55; 0.91)